Vaxart initiates sentinel cohort of Phase 2b oral COVID-19 vaccine trial; BARDA raises funding to $456M

Vaxart, Inc.

Modification No. 3 increased total estimated ceiling to ~$456.1M (+$3.2M) and allotted funding to ~$96.5M (+$30.8M).
Sentinel cohort of 400 participants (200 Vaxart oral pill, 200 mRNA comparator) begins; 30-day safety data will trigger enrollment of 10,000.
Trial will measure efficacy against symptomatic/asymptomatic disease, systemic and mucosal immunity, and safety.
Funding via Project NextGen (BARDA); full Phase 2b primary efficacy analysis at 12 months post-vaccination.
Vaxart's XBB vaccine construct and newly funded KP.2-targeting construct are part of the study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.